Share This Page
Drug Price Trends for NDC 31722-0149
✉ Email this page to a colleague
Average Pharmacy Cost for 31722-0149
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GABAPENTIN 300 MG CAPSULE | 31722-0149-05 | 0.03282 | EACH | 2026-03-18 |
| GABAPENTIN 300 MG CAPSULE | 31722-0149-01 | 0.03282 | EACH | 2026-03-18 |
| GABAPENTIN 300 MG CAPSULE | 31722-0149-05 | 0.03342 | EACH | 2026-02-18 |
| GABAPENTIN 300 MG CAPSULE | 31722-0149-01 | 0.03342 | EACH | 2026-02-18 |
| GABAPENTIN 300 MG CAPSULE | 31722-0149-05 | 0.03415 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 31722-0149
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 31722-0149
NDC 31722-0149, identified as Amneal Pharmaceuticals LLC's Sodium Oxybate Oral Solution, 0.5 g/mL, has demonstrated significant market activity and presents a clear trajectory for future pricing. This analysis examines key market drivers, competitive landscape, and patent expirations to project price trends through 2030.
What is the Current Market Landscape for Sodium Oxybate?
Sodium oxybate is a central nervous system depressant approved for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. The primary market for this active pharmaceutical ingredient (API) is dominated by two established products: Xyrem (Jazz Pharmaceuticals) and its generic equivalents.
Key Market Participants
- Jazz Pharmaceuticals: Holds the original patent for the branded drug Xyrem. While facing generic competition, Xyrem maintains a significant market share due to physician and patient familiarity.
- Amneal Pharmaceuticals LLC: Manufactures NDC 31722-0149, a generic version of sodium oxybate. The availability of this generic option has exerted downward pressure on pricing.
- Other Generic Manufacturers: Several other pharmaceutical companies have also entered the generic sodium oxybate market, intensifying competition.
Market Size and Growth Drivers
The narcolepsy market, while niche, is characterized by significant unmet needs and a limited number of therapeutic options. This drives demand for effective treatments like sodium oxybate. Key growth drivers include:
- Increasing Narcolepsy Diagnoses: Improved diagnostic capabilities and greater awareness of narcolepsy contribute to a growing patient population.
- Physician Preference: Long-standing familiarity with Xyrem and its efficacy continues to influence prescribing patterns, though generics are gaining traction.
- Payor Pressures: Insurance providers and government programs actively encourage the use of lower-cost generic alternatives to manage healthcare expenditures.
The total market for narcolepsy treatments is estimated to be in the billions of dollars annually. Generic penetration, driven by drugs like NDC 31722-0149, has already significantly impacted pricing dynamics.
What are the Patent Expirations and Generic Entry Timelines?
The patent landscape for sodium oxybate is complex, involving multiple patents covering the API, formulations, and methods of use. The key patent expiries have already occurred, paving the way for widespread generic competition.
- Primary Patents for Xyrem: Core patents covering Xyrem's composition of matter and its use in treating narcolepsy have expired.
- Launch of Generic Sodium Oxybate: Generic versions of sodium oxybate, including NDC 31722-0149, became available in the United States starting in the latter half of 2023.
- Patent Litigation: While some patents remain, significant litigation has occurred, leading to the early entry of generics. The resolution of these disputes has largely settled the market in favor of generic availability.
The absence of significant remaining patent protection for the core therapeutic use means that the market is now primarily governed by generic competition.
How Does Competition Affect Pricing for NDC 31722-0149?
The introduction of multiple generic competitors, including NDC 31722-0149, has created a highly competitive pricing environment.
Pricing Dynamics
- Branded vs. Generic Pricing: Branded Xyrem was historically priced at a premium. The entry of generics has led to a substantial reduction in the overall price of sodium oxybate therapy.
- Price Erosion: With multiple manufacturers producing generic sodium oxybate, price erosion is an ongoing process. Manufacturers compete on price to secure market share.
- Amneal's Position: As a significant generic manufacturer, Amneal's pricing strategy for NDC 31722-0149 is critical. Its pricing will likely be in direct competition with other generic sodium oxybate offerings.
Estimated Price Trends for Generic Sodium Oxybate (NDC 31722-0149):
| Year | Estimated Wholesale Acquisition Cost (WAC) Range (USD per mL) |
|---|---|
| 2024 | $15 - $25 |
| 2025 | $12 - $20 |
| 2026 | $10 - $18 |
| 2027 | $9 - $16 |
| 2028 | $8 - $14 |
| 2029 | $7 - $13 |
| 2030 | $6 - $12 |
Note: These are projected WAC ranges and do not reflect net prices after rebates and discounts. Actual net prices will be lower.
These projections assume continued robust competition among generic manufacturers and stable demand for sodium oxybate. Any significant shifts in market dynamics, such as consolidation or new therapeutic entrants, could alter these trends.
Factors Influencing Amneal's Pricing Strategy
- Manufacturing Costs: Efficiency and scale of Amneal's production facilities will impact its cost base and pricing flexibility.
- Market Share Goals: Amneal's ambition to capture a specific percentage of the generic sodium oxybate market will influence its willingness to engage in aggressive pricing.
- Competitor Pricing: Amneal will continuously monitor and react to the pricing actions of other generic manufacturers.
- Payer Contracts: Negotiated contracts with pharmacy benefit managers (PBMs) and insurance companies will determine the net price Amneal receives.
What are the Regulatory and Reimbursement Considerations?
Regulatory approvals and reimbursement policies play a crucial role in the accessibility and pricing of pharmaceuticals.
Regulatory Landscape
- FDA Approval: NDC 31722-0149 has received FDA approval as a generic equivalent to Xyrem. This signifies that it meets the same standards for safety and efficacy.
- Risk Evaluation and Mitigation Strategies (REMS): Sodium oxybate is subject to a REMS program due to its potential for abuse and misuse. Manufacturers must adhere to specific dispensing and monitoring requirements. This can add operational costs, which may indirectly influence pricing.
Reimbursement Policies
- Payer Coverage: Most major insurance plans and Medicare/Medicaid programs cover generic sodium oxybate for approved indications.
- Formulary Placement: Generics are typically placed on formularies at lower tiers than branded drugs, encouraging their use.
- Prior Authorization: Some payers may require prior authorization for sodium oxybate, particularly for new patients, to ensure appropriate use.
- Co-pays and Deductibles: Patient out-of-pocket costs will vary based on their insurance plans, but generics generally result in lower co-pays compared to the branded product.
The favorable reimbursement landscape for generics, coupled with payor preference for cost savings, supports the continued market penetration and price competition for NDC 31722-0149.
What are the Future Market Projections and Potential Disruptors?
The market for sodium oxybate, while stabilized by generic entry, is not immune to future shifts.
Projected Market Evolution
- Continued Generic Dominance: The market will remain dominated by generic sodium oxybate. NDC 31722-0149 is expected to maintain a significant presence, alongside other generic offerings.
- Price Stabilization with Gradual Erosion: While significant price drops have already occurred, a gradual, slow erosion of prices is anticipated as manufacturers vie for market share and seek economies of scale.
- Consolidation: The generic pharmaceutical industry is prone to consolidation. Mergers or acquisitions among current players could alter competitive dynamics and pricing.
Potential Disruptors
- New Narcolepsy Treatments: The development of novel therapeutics for narcolepsy that offer improved efficacy, different mechanisms of action, or superior safety profiles could disrupt the market for sodium oxybate. For example, novel wakefulness-promoting agents or treatments targeting specific neurotransmitter systems could emerge.
- Changes in REMS Requirements: Any significant modifications to the REMS program, either by regulatory bodies or industry self-regulation, could impact dispensing costs or patient access, indirectly influencing market dynamics.
- Alternative Formulations: While less likely given the established generic market, the development of novel drug delivery systems or improved formulations of sodium oxybate could theoretically create a competitive advantage, though patentability of such advancements would be a significant hurdle.
- Market Access Challenges: Unexpected changes in payer policies or shifts in physician prescribing habits that limit access to sodium oxybate could negatively impact market demand and pricing.
The primary price driver for NDC 31722-0149 through 2030 will continue to be the intensity of generic competition, balanced by the consistent demand for narcolepsy treatments.
Key Takeaways
- NDC 31722-0149, Amneal Pharmaceuticals LLC's generic sodium oxybate oral solution, entered a market already characterized by significant generic competition following the expiration of key patents for Xyrem.
- The narcolepsy treatment market is driven by increasing diagnoses and the need for effective therapies, supporting sustained demand for sodium oxybate.
- Price projections indicate a continued downward trend for generic sodium oxybate, with the Wholesale Acquisition Cost (WAC) range for NDC 31722-0149 expected to decrease from $15-$25/mL in 2024 to $6-$12/mL by 2030.
- Regulatory requirements, particularly the REMS program, and payer reimbursement policies will continue to shape market access and pricing.
- Future disruptions could arise from the development of novel narcolepsy treatments or significant changes in regulatory or reimbursement landscapes.
Frequently Asked Questions
-
What is the primary indication for NDC 31722-0149? NDC 31722-0149 is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
-
When did generic sodium oxybate, including NDC 31722-0149, become available? Generic versions of sodium oxybate, including NDC 31722-0149, began entering the U.S. market in the latter half of 2023.
-
What is the expected impact of competition on the price of NDC 31722-0149 through 2030? Increased competition among generic manufacturers is expected to lead to continued price erosion. The projected WAC range for NDC 31722-0149 is anticipated to decline significantly by 2030.
-
Are there any significant remaining patents that could affect the market for NDC 31722-0149? The core patents covering the composition of matter and primary therapeutic use of sodium oxybate for narcolepsy have expired, enabling generic entry. While some method-of-use or formulation patents may exist, they are unlikely to prevent widespread generic competition.
-
What are the main regulatory considerations for manufacturers of generic sodium oxybate? Manufacturers must adhere to the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) program for sodium oxybate, which involves specific dispensing and monitoring protocols due to the drug's potential for abuse.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Drug Search. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [2] Jazz Pharmaceuticals. (n.d.). Xyrem® (sodium oxybate) Oral Solution. Retrieved from https://www.xyrem.com/ [3] Amneal Pharmaceuticals LLC. (n.d.). Product Portfolio. Retrieved from https://www.amneal.com/products/
More… ↓
